Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)
March 05 2015 - 5:21PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 14D-9C
(RULE 14d-101)
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
PHARMACYCLICS, INC.
(Name of Subject Company)
PHARMACYCLICS, INC.
(Name of Persons Filing Statement)
Common Stock,
par value $0.0001 per share
(Title of Class of Securities)
716933106
(CUSIP Number
of Class of Securities)
Robert W. Duggan
Chairman and Chief Executive Officer
995 E. Arques Avenue
Sunnyvale, California 94085-4521
(408) 774-0330
(Name,
address and telephone numbers of person authorized to receive notices and
communications on behalf of the persons filing statement)
With copies to:
Robert T. Ishii
Denny
Kwon
Wilson Sonsini Goodrich & Rosati, P.C.
One Market Place
Spear
Tower, Suite 3300
San Francisco, CA 94105
(415) 947-2000
| x |
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
The information set forth under Item 8.01 of the Current Report on Form 8-K filed by
Pharmacyclics, Inc. on March 5, 2015 (including all exhibits attached thereto) is incorporated herein by reference.
(MM) (NASDAQ:PCYC)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:PCYC)
Historical Stock Chart
From Jul 2023 to Jul 2024
